News Release

May 25, 2022

ORGANON CANADA, A WOMEN’S HEALTH COMPANY, IS PLEASED WITH THE GOVERNMENT OF QUEBEC’S DECISION TO EXPAND UNIVERSAL HEALTH CARE COVERAGE TO INCLUDE MORE HORMONAL THERAPY OPTIONS, WHICH WILL PROVIDE MORE CHOICES TO WOMEN EXPERIENCING SYMPTOMS FROM MENOPAUSE

PROMETRIUM® AND ESTROGEL® ARE NOW COVERED WITHOUT ANY CONDITIONS BY THE RÉGIE DE L’ASSURANCE MALADIE DU QUÉBEC (RAMQ)

Kirkland, Quebec, May 25, 2022 – Organon Canada (NYSE: OGN), the only company of its size focused on women’s health, welcomes the addition of PROMETRIUM® and ESTROGEL® to the regular list of drugs covered by the Régie de l’assurance maladie du Québec (RAMQ).

“As a women’s health company, we are proud to have worked, during our very first year of operation, with the Quebec Ministry of Health and Social Services towards giving women in Quebec access to more hormonal therapy options that meet their needs,” said Michael Casia, President and Managing Director, Organon Canada.

Since its launch on June 3, 2021, Organon Canada has had a singular vision : to make a better and healthier every day for every woman. The company made a commitment to listen to women to hear – and understand – their health needs, including during menopause, and to help find solutions to problems as yet unmet.

“Organon Canada intends to build on this momentum by focusing on women’s reproductive health, and the health issues and diseases that affect women specifically,” said Amy Cairns, Executive Director, Women’s Health and Established Brands. “We will continue to listen to their health needs while working to make a difference.”

About Organon

Organon is a global health care company formed through a spin-off from Merck (NYSE: MRK), known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the women’s health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investment in innovation and future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast-growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,500 employees with headquarters located in Jersey City, New Jersey.

For more information, connect with us on LinkedIn and Twitter.